Gast ::
| Hauptseite > Publikationsdatenbank > Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens > print |
| Hauptseite > Publikationsdatenbank > Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens > print |
| 001 | 1052352 | ||
| 005 | 20260123203315.0 | ||
| 024 | 7 | _ | |a 10.1007/s00415-025-13573-4 |2 doi |
| 024 | 7 | _ | |a 0367-004X |2 ISSN |
| 024 | 7 | _ | |a 0012-1037 |2 ISSN |
| 024 | 7 | _ | |a 0340-5354 |2 ISSN |
| 024 | 7 | _ | |a 1432-1459 |2 ISSN |
| 024 | 7 | _ | |a 10.34734/FZJ-2026-00954 |2 datacite_doi |
| 037 | _ | _ | |a FZJ-2026-00954 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Konitsioti, Agni M. |0 0000-0002-7296-4349 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens |
| 260 | _ | _ | |a [Darmstadt] |c 2026 |b Steinkopff |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1769162857_19119 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Funding: Open Access funding enabled and organized by Projekt DEAL. The study was supported by an unrestricted grant from Novartis. |
| 520 | _ | _ | |a BackgroundSerum neurofilament light chain (sNfL) is an established biomarker of disease activity and progression in persons with multiple sclerosis (PwMS), with studies showing elevated sNfL levels during relapses and positive associations with disability scores.Objective To assess sNfL levels in PwMS receiving different disease-modifying therapies (DMTs), with a particular focus on extended-interval dosing (EID) regimens in real-world clinical practice.MethodsIn this two-center cross-sectional study, 172 PwMS without relapses in the preceding three months were included (University Hospital Cologne, n = 125; University Hospital Mainz, n = 47). Patients were categorized into the following groups: (1) low-efficacy DMT (leDMT; n = 8), (2) natalizumab standard-interval dosing (SID; every 4 weeks; n = 7), (3) natalizumab EID (every 6–8 weeks; n = 53), (4) ofatumumab (n = 17), (5) ocrelizumab SID (every 6 months; n = 48), (6) ocrelizumab EID (every 9 months; n = 17), and (7) no DMT (n = 19). sNfL levels were measured once in a cross-sectional design using an electrochemiluminescence immunoassay.Results No significant differences in sNfL levels were observed across DMT subgroups in the ANCOVA analysis after adjusting for age and the presence of new T2 lesions on the most recent cranial MRI. However, PwMS receiving DMTs showed lower sNfL levels compared with untreated patients. Notably EID of ocrelizumab (every 9 months; 1.56 pg/mL, 95% CI 1.26–1.85) and natalizumab (every 8 weeks; 1.46 pg/mL, 95% CI 1.29–1.64) was not associated with higher sNfL levels compared to standard interval dosing (SID) of ocrelizumab (1.45 pg/mL, 95% CI 1.27–1.63) or natalizumab (1.13 pg/mL, 95% CI 0.68–1.58).Conclusion EID regimens were not associated with increased sNfL levels, suggesting that they may effectively limit neuroaxonal damage. Larger studies that assess the added value sNfL monitoring for safely personalizing treatment intervals in PwMS with initially active disease are needed. |
| 536 | _ | _ | |a 5251 - Multilevel Brain Organization and Variability (POF4-525) |0 G:(DE-HGF)POF4-5251 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Schweitzer, Finja |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Johannis, Wibke |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Steffen, Falk |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Bittner, Stefan |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Fink, Gereon R. |0 P:(DE-Juel1)131720 |b 5 |u fzj |
| 700 | 1 | _ | |a Schroeter, Michael |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Warnke, Clemens |0 P:(DE-HGF)0 |b 7 |
| 773 | _ | _ | |a 10.1007/s00415-025-13573-4 |g Vol. 273, no. 1, p. 34 |0 PERI:(DE-600)1421299-7 |n 1 |p 34 |t Journal of neurology |v 273 |y 2026 |x 0367-004X |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1052352/files/PDF.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:1052352 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)131720 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5251 |x 0 |
| 914 | 1 | _ | |y 2026 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-10 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-10 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-10 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-10 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|